nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—ALB—focal segmental glomerulosclerosis	0.277	1	CbGaD
Imatinib—ABCG2—Cyclosporine—focal segmental glomerulosclerosis	0.0858	0.21	CbGbCtD
Imatinib—CYP3A7—Cyclosporine—focal segmental glomerulosclerosis	0.0634	0.155	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Cyclosporine—focal segmental glomerulosclerosis	0.0634	0.155	CbGbCtD
Imatinib—CYP3A5—Cyclosporine—focal segmental glomerulosclerosis	0.0475	0.116	CbGbCtD
Imatinib—CYP2C19—Cyclosporine—focal segmental glomerulosclerosis	0.0384	0.0938	CbGbCtD
Imatinib—CYP2C9—Cyclosporine—focal segmental glomerulosclerosis	0.0319	0.078	CbGbCtD
Imatinib—ABCB1—Cyclosporine—focal segmental glomerulosclerosis	0.0309	0.0757	CbGbCtD
Imatinib—CYP2D6—Cyclosporine—focal segmental glomerulosclerosis	0.0292	0.0713	CbGbCtD
Imatinib—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0185	0.0453	CbGbCtD
Imatinib—Hypotrichosis—Cyclosporine—focal segmental glomerulosclerosis	0.012	0.0816	CcSEcCtD
Imatinib—SLC22A2—nephron—focal segmental glomerulosclerosis	0.00907	0.116	CbGeAlD
Imatinib—DDR1—nephron tubule—focal segmental glomerulosclerosis	0.00456	0.0582	CbGeAlD
Imatinib—ABCA3—cortex of kidney—focal segmental glomerulosclerosis	0.00423	0.0539	CbGeAlD
Imatinib—DDR1—cortex of kidney—focal segmental glomerulosclerosis	0.0039	0.0498	CbGeAlD
Imatinib—Skin cancer—Cyclosporine—focal segmental glomerulosclerosis	0.00366	0.0248	CcSEcCtD
Imatinib—KIT—endothelium—focal segmental glomerulosclerosis	0.0036	0.0459	CbGeAlD
Imatinib—Papilloedema—Cyclosporine—focal segmental glomerulosclerosis	0.00357	0.0242	CcSEcCtD
Imatinib—Pigmentation disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0034	0.0231	CcSEcCtD
Imatinib—Bullous eruption—Cyclosporine—focal segmental glomerulosclerosis	0.00287	0.0195	CcSEcCtD
Imatinib—PIP4K2C—nephron tubule—focal segmental glomerulosclerosis	0.00282	0.0359	CbGeAlD
Imatinib—CA7—kidney—focal segmental glomerulosclerosis	0.00258	0.0328	CbGeAlD
Imatinib—PIP4K2C—cortex of kidney—focal segmental glomerulosclerosis	0.00241	0.0307	CbGeAlD
Imatinib—Night sweats—Cyclosporine—focal segmental glomerulosclerosis	0.0021	0.0143	CcSEcCtD
Imatinib—NQO2—nephron tubule—focal segmental glomerulosclerosis	0.00207	0.0264	CbGeAlD
Imatinib—CYP3A7-CYP3A51P—nephron tubule—focal segmental glomerulosclerosis	0.00203	0.0259	CbGeAlD
Imatinib—SLC22A2—nephron tubule—focal segmental glomerulosclerosis	0.00196	0.025	CbGeAlD
Imatinib—Gastric ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00195	0.0132	CcSEcCtD
Imatinib—Polyp—Cyclosporine—focal segmental glomerulosclerosis	0.00186	0.0126	CcSEcCtD
Imatinib—Optic neuritis—Cyclosporine—focal segmental glomerulosclerosis	0.00184	0.0125	CcSEcCtD
Imatinib—NQO2—kidney—focal segmental glomerulosclerosis	0.00182	0.0232	CbGeAlD
Imatinib—Folliculitis—Cyclosporine—focal segmental glomerulosclerosis	0.0018	0.0122	CcSEcCtD
Imatinib—Psoriasis—Cyclosporine—focal segmental glomerulosclerosis	0.0018	0.0122	CcSEcCtD
Imatinib—Hypomagnesaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00179	0.0121	CcSEcCtD
Imatinib—NQO2—cortex of kidney—focal segmental glomerulosclerosis	0.00177	0.0226	CbGeAlD
Imatinib—Nail disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00175	0.0119	CcSEcCtD
Imatinib—CYP3A7-CYP3A51P—cortex of kidney—focal segmental glomerulosclerosis	0.00174	0.0222	CbGeAlD
Imatinib—SLC22A2—kidney—focal segmental glomerulosclerosis	0.00172	0.0219	CbGeAlD
Imatinib—Cyst—Cyclosporine—focal segmental glomerulosclerosis	0.0017	0.0115	CcSEcCtD
Imatinib—Digestion impaired—Cyclosporine—focal segmental glomerulosclerosis	0.0017	0.0115	CcSEcCtD
Imatinib—SLC22A2—cortex of kidney—focal segmental glomerulosclerosis	0.00168	0.0214	CbGeAlD
Imatinib—CA12—kidney—focal segmental glomerulosclerosis	0.00167	0.0213	CbGeAlD
Imatinib—SLC47A1—nephron tubule—focal segmental glomerulosclerosis	0.00166	0.0211	CbGeAlD
Imatinib—KIT—nephron tubule—focal segmental glomerulosclerosis	0.00165	0.021	CbGeAlD
Imatinib—PTGS1—endothelium—focal segmental glomerulosclerosis	0.00165	0.021	CbGeAlD
Imatinib—Myopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00162	0.011	CcSEcCtD
Imatinib—Interstitial lung disease—Cyclosporine—focal segmental glomerulosclerosis	0.0016	0.0109	CcSEcCtD
Imatinib—Thrombosis—Cyclosporine—focal segmental glomerulosclerosis	0.0016	0.0109	CcSEcCtD
Imatinib—Herpes zoster—Cyclosporine—focal segmental glomerulosclerosis	0.00151	0.0102	CcSEcCtD
Imatinib—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.00147	0.00996	CcSEcCtD
Imatinib—Fungal infection—Cyclosporine—focal segmental glomerulosclerosis	0.00147	0.00996	CcSEcCtD
Imatinib—SLC47A1—kidney—focal segmental glomerulosclerosis	0.00146	0.0186	CbGeAlD
Imatinib—KIT—kidney—focal segmental glomerulosclerosis	0.00145	0.0185	CbGeAlD
Imatinib—Hyperaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00145	0.0098	CcSEcCtD
Imatinib—ABL1—nephron tubule—focal segmental glomerulosclerosis	0.00144	0.0183	CbGeAlD
Imatinib—SLC47A1—cortex of kidney—focal segmental glomerulosclerosis	0.00142	0.0181	CbGeAlD
Imatinib—PDGFRB—kidney—focal segmental glomerulosclerosis	0.00142	0.018	CbGeAlD
Imatinib—KIT—cortex of kidney—focal segmental glomerulosclerosis	0.00141	0.018	CbGeAlD
Imatinib—Rigors—Cyclosporine—focal segmental glomerulosclerosis	0.00139	0.00942	CcSEcCtD
Imatinib—PDGFRB—cortex of kidney—focal segmental glomerulosclerosis	0.00138	0.0176	CbGeAlD
Imatinib—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.00133	0.00901	CcSEcCtD
Imatinib—CA1—kidney—focal segmental glomerulosclerosis	0.00133	0.0169	CbGeAlD
Imatinib—Rhabdomyolysis—Cyclosporine—focal segmental glomerulosclerosis	0.00128	0.0087	CcSEcCtD
Imatinib—Musculoskeletal stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.00126	0.00858	CcSEcCtD
Imatinib—ABL1—kidney—focal segmental glomerulosclerosis	0.00126	0.0161	CbGeAlD
Imatinib—Hyperbilirubinaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00125	0.00846	CcSEcCtD
Imatinib—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.00125	0.00846	CcSEcCtD
Imatinib—Herpes simplex—Cyclosporine—focal segmental glomerulosclerosis	0.00123	0.00835	CcSEcCtD
Imatinib—Lacrimation increased—Cyclosporine—focal segmental glomerulosclerosis	0.00123	0.00835	CcSEcCtD
Imatinib—ABL1—cortex of kidney—focal segmental glomerulosclerosis	0.00123	0.0157	CbGeAlD
Imatinib—Hyperuricaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00122	0.00829	CcSEcCtD
Imatinib—SLC22A1—kidney—focal segmental glomerulosclerosis	0.00122	0.0155	CbGeAlD
Imatinib—Gout—Cyclosporine—focal segmental glomerulosclerosis	0.00121	0.00824	CcSEcCtD
Imatinib—Hearing impaired—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.00808	CcSEcCtD
Imatinib—Cataract—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.00808	CcSEcCtD
Imatinib—Creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.00808	CcSEcCtD
Imatinib—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.00116	0.00784	CcSEcCtD
Imatinib—Eructation—Cyclosporine—focal segmental glomerulosclerosis	0.00111	0.00756	CcSEcCtD
Imatinib—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00111	0.00756	CcSEcCtD
Imatinib—Influenza like illness—Cyclosporine—focal segmental glomerulosclerosis	0.0011	0.00747	CcSEcCtD
Imatinib—Fluid retention—Cyclosporine—focal segmental glomerulosclerosis	0.00108	0.0073	CcSEcCtD
Imatinib—Oesophagitis—Cyclosporine—focal segmental glomerulosclerosis	0.00104	0.00703	CcSEcCtD
Imatinib—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.00103	0.00696	CcSEcCtD
Imatinib—Gynaecomastia—Cyclosporine—focal segmental glomerulosclerosis	0.00101	0.00688	CcSEcCtD
Imatinib—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.000984	0.00668	CcSEcCtD
Imatinib—CA2—nephron tubule—focal segmental glomerulosclerosis	0.000977	0.0125	CbGeAlD
Imatinib—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000965	0.00655	CcSEcCtD
Imatinib—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.000929	0.0063	CcSEcCtD
Imatinib—Deafness—Cyclosporine—focal segmental glomerulosclerosis	0.000921	0.00624	CcSEcCtD
Imatinib—Vascular purpura—Cyclosporine—focal segmental glomerulosclerosis	0.000921	0.00624	CcSEcCtD
Imatinib—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.000916	0.00622	CcSEcCtD
Imatinib—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.000916	0.00622	CcSEcCtD
Imatinib—Eye pain—Cyclosporine—focal segmental glomerulosclerosis	0.000912	0.00619	CcSEcCtD
Imatinib—ABCG2—nephron tubule—focal segmental glomerulosclerosis	0.000905	0.0115	CbGeAlD
Imatinib—Libido decreased—Cyclosporine—focal segmental glomerulosclerosis	0.000888	0.00602	CcSEcCtD
Imatinib—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000876	0.00594	CcSEcCtD
Imatinib—Dermatitis bullous—Cyclosporine—focal segmental glomerulosclerosis	0.000862	0.00584	CcSEcCtD
Imatinib—CA2—kidney—focal segmental glomerulosclerosis	0.000859	0.011	CbGeAlD
Imatinib—Purpura—Cyclosporine—focal segmental glomerulosclerosis	0.000854	0.0058	CcSEcCtD
Imatinib—Arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.000847	0.00575	CcSEcCtD
Imatinib—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.000844	0.00572	CcSEcCtD
Imatinib—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000844	0.00572	CcSEcCtD
Imatinib—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.00084	0.0057	CcSEcCtD
Imatinib—CYP3A5—nephron tubule—focal segmental glomerulosclerosis	0.00084	0.0107	CbGeAlD
Imatinib—CA2—cortex of kidney—focal segmental glomerulosclerosis	0.000837	0.0107	CbGeAlD
Imatinib—Disturbance in sexual arousal—Cyclosporine—focal segmental glomerulosclerosis	0.000817	0.00554	CcSEcCtD
Imatinib—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.000811	0.0055	CcSEcCtD
Imatinib—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.000771	0.00523	CcSEcCtD
Imatinib—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.000755	0.00512	CcSEcCtD
Imatinib—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.000752	0.0051	CcSEcCtD
Imatinib—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000744	0.00505	CcSEcCtD
Imatinib—Cramp muscle—Cyclosporine—focal segmental glomerulosclerosis	0.000742	0.00503	CcSEcCtD
Imatinib—CYP3A5—kidney—focal segmental glomerulosclerosis	0.000738	0.00941	CbGeAlD
Imatinib—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.000729	0.00494	CcSEcCtD
Imatinib—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.000726	0.00493	CcSEcCtD
Imatinib—CYP3A5—cortex of kidney—focal segmental glomerulosclerosis	0.000719	0.00917	CbGeAlD
Imatinib—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.000716	0.00486	CcSEcCtD
Imatinib—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.000712	0.00483	CcSEcCtD
Imatinib—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000698	0.00473	CcSEcCtD
Imatinib—Sweating increased—Cyclosporine—focal segmental glomerulosclerosis	0.000693	0.0047	CcSEcCtD
Imatinib—PTGS1—kidney—focal segmental glomerulosclerosis	0.000663	0.00846	CbGeAlD
Imatinib—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000661	0.00449	CcSEcCtD
Imatinib—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.000657	0.00446	CcSEcCtD
Imatinib—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.000648	0.00439	CcSEcCtD
Imatinib—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.000644	0.00437	CcSEcCtD
Imatinib—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000642	0.00435	CcSEcCtD
Imatinib—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.000638	0.00433	CcSEcCtD
Imatinib—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.000635	0.0043	CcSEcCtD
Imatinib—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.000635	0.0043	CcSEcCtD
Imatinib—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.000633	0.00429	CcSEcCtD
Imatinib—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.000626	0.00424	CcSEcCtD
Imatinib—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.000624	0.00423	CcSEcCtD
Imatinib—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.000622	0.00422	CcSEcCtD
Imatinib—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.000622	0.00422	CcSEcCtD
Imatinib—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000619	0.0042	CcSEcCtD
Imatinib—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.000619	0.0042	CcSEcCtD
Imatinib—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.000617	0.00418	CcSEcCtD
Imatinib—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000617	0.00418	CcSEcCtD
Imatinib—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.000605	0.0041	CcSEcCtD
Imatinib—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.0006	0.00407	CcSEcCtD
Imatinib—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.000599	0.00406	CcSEcCtD
Imatinib—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.000595	0.00404	CcSEcCtD
Imatinib—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.000573	0.00388	CcSEcCtD
Imatinib—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.000571	0.00387	CcSEcCtD
Imatinib—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00057	0.00386	CcSEcCtD
Imatinib—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00057	0.00386	CcSEcCtD
Imatinib—Hypoaesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000567	0.00384	CcSEcCtD
Imatinib—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.000565	0.00384	CcSEcCtD
Imatinib—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000563	0.00382	CcSEcCtD
Imatinib—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00056	0.0038	CcSEcCtD
Imatinib—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000558	0.00379	CcSEcCtD
Imatinib—CYP3A4—kidney—focal segmental glomerulosclerosis	0.000554	0.00706	CbGeAlD
Imatinib—CYP2D6—kidney—focal segmental glomerulosclerosis	0.000545	0.00695	CbGeAlD
Imatinib—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.000531	0.0036	CcSEcCtD
Imatinib—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.000529	0.00359	CcSEcCtD
Imatinib—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000517	0.00351	CcSEcCtD
Imatinib—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000513	0.00348	CcSEcCtD
Imatinib—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.000511	0.00347	CcSEcCtD
Imatinib—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.000509	0.00345	CcSEcCtD
Imatinib—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.000503	0.00341	CcSEcCtD
Imatinib—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000499	0.00339	CcSEcCtD
Imatinib—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000496	0.00336	CcSEcCtD
Imatinib—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.000489	0.00331	CcSEcCtD
Imatinib—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.000486	0.00329	CcSEcCtD
Imatinib—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.000477	0.00323	CcSEcCtD
Imatinib—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000467	0.00317	CcSEcCtD
Imatinib—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.000465	0.00315	CcSEcCtD
Imatinib—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00046	0.00312	CcSEcCtD
Imatinib—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000458	0.00311	CcSEcCtD
Imatinib—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.000453	0.00307	CcSEcCtD
Imatinib—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.000447	0.00303	CcSEcCtD
Imatinib—ABCB1—nephron tubule—focal segmental glomerulosclerosis	0.000446	0.00569	CbGeAlD
Imatinib—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.000446	0.00302	CcSEcCtD
Imatinib—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000444	0.00301	CcSEcCtD
Imatinib—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000433	0.00294	CcSEcCtD
Imatinib—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.00043	0.00291	CcSEcCtD
Imatinib—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000428	0.0029	CcSEcCtD
Imatinib—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000422	0.00286	CcSEcCtD
Imatinib—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000422	0.00286	CcSEcCtD
Imatinib—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000422	0.00286	CcSEcCtD
Imatinib—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000421	0.00285	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000419	0.00284	CcSEcCtD
Imatinib—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000417	0.00283	CcSEcCtD
Imatinib—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000413	0.0028	CcSEcCtD
Imatinib—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.000408	0.00277	CcSEcCtD
Imatinib—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.000405	0.00275	CcSEcCtD
Imatinib—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000405	0.00275	CcSEcCtD
Imatinib—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000402	0.00273	CcSEcCtD
Imatinib—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000397	0.00269	CcSEcCtD
Imatinib—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000396	0.00269	CcSEcCtD
Imatinib—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000393	0.00267	CcSEcCtD
Imatinib—ABCB1—kidney—focal segmental glomerulosclerosis	0.000392	0.005	CbGeAlD
Imatinib—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.000391	0.00265	CcSEcCtD
Imatinib—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.000386	0.00262	CcSEcCtD
Imatinib—ABCB1—cortex of kidney—focal segmental glomerulosclerosis	0.000382	0.00487	CbGeAlD
Imatinib—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000369	0.0025	CcSEcCtD
Imatinib—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000366	0.00248	CcSEcCtD
Imatinib—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000363	0.00247	CcSEcCtD
Imatinib—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000361	0.00245	CcSEcCtD
Imatinib—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.00036	0.00244	CcSEcCtD
Imatinib—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000356	0.00242	CcSEcCtD
Imatinib—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000352	0.00239	CcSEcCtD
Imatinib—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000349	0.00237	CcSEcCtD
Imatinib—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000349	0.00237	CcSEcCtD
Imatinib—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000346	0.00235	CcSEcCtD
Imatinib—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000346	0.00235	CcSEcCtD
Imatinib—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000334	0.00226	CcSEcCtD
Imatinib—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000331	0.00224	CcSEcCtD
Imatinib—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000322	0.00218	CcSEcCtD
Imatinib—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00032	0.00217	CcSEcCtD
Imatinib—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00032	0.00217	CcSEcCtD
Imatinib—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000298	0.00202	CcSEcCtD
Imatinib—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00029	0.00197	CcSEcCtD
Imatinib—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000286	0.00194	CcSEcCtD
Imatinib—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000277	0.00188	CcSEcCtD
Imatinib—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000268	0.00182	CcSEcCtD
Imatinib—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000257	0.00175	CcSEcCtD
Imatinib—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000255	0.00173	CcSEcCtD
Imatinib—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000255	0.00173	CcSEcCtD
Imatinib—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000254	0.00172	CcSEcCtD
Imatinib—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00024	0.00163	CcSEcCtD
Imatinib—CA7—Metabolism—AGT—focal segmental glomerulosclerosis	4.47e-05	0.000509	CbGpPWpGaD
Imatinib—ABL1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	4.41e-05	0.000502	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—CD40LG—focal segmental glomerulosclerosis	4.4e-05	0.000501	CbGpPWpGaD
Imatinib—ALB—Platelet degranulation—TGFB1—focal segmental glomerulosclerosis	4.35e-05	0.000496	CbGpPWpGaD
Imatinib—LCK—Immune System—MYH9—focal segmental glomerulosclerosis	4.34e-05	0.000494	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	4.34e-05	0.000494	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD79A—focal segmental glomerulosclerosis	4.33e-05	0.000494	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	4.31e-05	0.000491	CbGpPWpGaD
Imatinib—SLC22A2—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	4.3e-05	0.00049	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	4.3e-05	0.000489	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	4.29e-05	0.000488	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	4.26e-05	0.000485	CbGpPWpGaD
Imatinib—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—focal segmental glomerulosclerosis	4.15e-05	0.000473	CbGpPWpGaD
Imatinib—CA9—Metabolism—GNAQ—focal segmental glomerulosclerosis	4.14e-05	0.000472	CbGpPWpGaD
Imatinib—CA12—Metabolism—AGT—focal segmental glomerulosclerosis	4.14e-05	0.000471	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	4.07e-05	0.000463	CbGpPWpGaD
Imatinib—SLC22A1—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	4.01e-05	0.000457	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—TGFB1—focal segmental glomerulosclerosis	3.85e-05	0.000439	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—FN1—focal segmental glomerulosclerosis	3.85e-05	0.000439	CbGpPWpGaD
Imatinib—KIT—Immune System—CD79A—focal segmental glomerulosclerosis	3.84e-05	0.000437	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TRPC6—focal segmental glomerulosclerosis	3.81e-05	0.000434	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—NOS2—focal segmental glomerulosclerosis	3.8e-05	0.000433	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	3.79e-05	0.000431	CbGpPWpGaD
Imatinib—CA14—Metabolism—ALB—focal segmental glomerulosclerosis	3.77e-05	0.000429	CbGpPWpGaD
Imatinib—CA2—Metabolism—LPL—focal segmental glomerulosclerosis	3.7e-05	0.000421	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	3.68e-05	0.000419	CbGpPWpGaD
Imatinib—CA6—Metabolism—ALB—focal segmental glomerulosclerosis	3.67e-05	0.000418	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	3.66e-05	0.000417	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD79A—focal segmental glomerulosclerosis	3.64e-05	0.000414	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	3.6e-05	0.000411	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	3.58e-05	0.000407	CbGpPWpGaD
Imatinib—CA1—Metabolism—LPL—focal segmental glomerulosclerosis	3.55e-05	0.000404	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD40LG—focal segmental glomerulosclerosis	3.53e-05	0.000402	CbGpPWpGaD
Imatinib—ABL1—Axon guidance—MMP9—focal segmental glomerulosclerosis	3.51e-05	0.000399	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	3.48e-05	0.000396	CbGpPWpGaD
Imatinib—CA7—Metabolism—ALB—focal segmental glomerulosclerosis	3.43e-05	0.00039	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	3.4e-05	0.000387	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—MMP2—focal segmental glomerulosclerosis	3.33e-05	0.000379	CbGpPWpGaD
Imatinib—ALB—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	3.3e-05	0.000376	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	3.3e-05	0.000376	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD79A—focal segmental glomerulosclerosis	3.27e-05	0.000373	CbGpPWpGaD
Imatinib—LCK—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	3.23e-05	0.000368	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	3.21e-05	0.000366	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	3.2e-05	0.000365	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—ALB—focal segmental glomerulosclerosis	3.2e-05	0.000364	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD79A—focal segmental glomerulosclerosis	3.19e-05	0.000364	CbGpPWpGaD
Imatinib—ALB—Hemostasis—GNAQ—focal segmental glomerulosclerosis	3.19e-05	0.000363	CbGpPWpGaD
Imatinib—CA12—Metabolism—ALB—focal segmental glomerulosclerosis	3.18e-05	0.000362	CbGpPWpGaD
Imatinib—LCK—Hemostasis—FN1—focal segmental glomerulosclerosis	3.17e-05	0.000361	CbGpPWpGaD
Imatinib—CA2—Metabolism—AGT—focal segmental glomerulosclerosis	3.16e-05	0.00036	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	3.16e-05	0.00036	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	3.15e-05	0.000359	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	3.14e-05	0.000358	CbGpPWpGaD
Imatinib—LCK—Hemostasis—NOS2—focal segmental glomerulosclerosis	3.13e-05	0.000357	CbGpPWpGaD
Imatinib—KIT—Immune System—CD40LG—focal segmental glomerulosclerosis	3.13e-05	0.000357	CbGpPWpGaD
Imatinib—CA9—Metabolism—LPL—focal segmental glomerulosclerosis	3.12e-05	0.000355	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	3.06e-05	0.000349	CbGpPWpGaD
Imatinib—CA1—Metabolism—AGT—focal segmental glomerulosclerosis	3.03e-05	0.000346	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.99e-05	0.000341	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.97e-05	0.000339	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD40LG—focal segmental glomerulosclerosis	2.96e-05	0.000338	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	2.94e-05	0.000335	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	2.93e-05	0.000334	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	2.91e-05	0.000331	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	2.89e-05	0.000329	CbGpPWpGaD
Imatinib—KIT—Disease—LPL—focal segmental glomerulosclerosis	2.84e-05	0.000323	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2.83e-05	0.000322	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.79e-05	0.000318	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.71e-05	0.000309	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.69e-05	0.000307	CbGpPWpGaD
Imatinib—PDGFRA—Disease—LPL—focal segmental glomerulosclerosis	2.69e-05	0.000306	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.68e-05	0.000305	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD40LG—focal segmental glomerulosclerosis	2.67e-05	0.000304	CbGpPWpGaD
Imatinib—CA9—Metabolism—AGT—focal segmental glomerulosclerosis	2.67e-05	0.000304	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.64e-05	0.000301	CbGpPWpGaD
Imatinib—LCK—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	2.64e-05	0.000301	CbGpPWpGaD
Imatinib—LCK—Hemostasis—ALB—focal segmental glomerulosclerosis	2.63e-05	0.0003	CbGpPWpGaD
Imatinib—LCK—Immune System—CD79A—focal segmental glomerulosclerosis	2.63e-05	0.000299	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD40LG—focal segmental glomerulosclerosis	2.6e-05	0.000296	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—LIPC—focal segmental glomerulosclerosis	2.58e-05	0.000294	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2.58e-05	0.000294	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.57e-05	0.000293	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—LIPC—focal segmental glomerulosclerosis	2.56e-05	0.000291	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—LIPC—focal segmental glomerulosclerosis	2.55e-05	0.000291	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	2.5e-05	0.000285	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—MMP9—focal segmental glomerulosclerosis	2.5e-05	0.000285	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.5e-05	0.000285	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—LIPC—focal segmental glomerulosclerosis	2.48e-05	0.000283	CbGpPWpGaD
Imatinib—CA2—Metabolism—ALB—focal segmental glomerulosclerosis	2.43e-05	0.000277	CbGpPWpGaD
Imatinib—PDGFRB—Disease—LPL—focal segmental glomerulosclerosis	2.42e-05	0.000276	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.42e-05	0.000275	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—LIPC—focal segmental glomerulosclerosis	2.38e-05	0.000271	CbGpPWpGaD
Imatinib—CA1—Metabolism—ALB—focal segmental glomerulosclerosis	2.33e-05	0.000265	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.32e-05	0.000264	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.29e-05	0.00026	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—CTGF—focal segmental glomerulosclerosis	2.27e-05	0.000259	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—CTGF—focal segmental glomerulosclerosis	2.25e-05	0.000257	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.25e-05	0.000257	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—CTGF—focal segmental glomerulosclerosis	2.25e-05	0.000256	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	2.23e-05	0.000254	CbGpPWpGaD
Imatinib—KIT—Disease—NOS2—focal segmental glomerulosclerosis	2.22e-05	0.000252	CbGpPWpGaD
Imatinib—ABCG2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.21e-05	0.000252	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2.2e-05	0.000251	CbGpPWpGaD
Imatinib—SLC22A2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.19e-05	0.000249	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—CTGF—focal segmental glomerulosclerosis	2.18e-05	0.000249	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	2.18e-05	0.000249	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.16e-05	0.000246	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.15e-05	0.000245	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.14e-05	0.000244	CbGpPWpGaD
Imatinib—LCK—Immune System—CD40LG—focal segmental glomerulosclerosis	2.14e-05	0.000244	CbGpPWpGaD
Imatinib—PDGFRA—Disease—NOS2—focal segmental glomerulosclerosis	2.1e-05	0.000239	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—CTGF—focal segmental glomerulosclerosis	2.1e-05	0.000239	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.09e-05	0.000239	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.08e-05	0.000236	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.07e-05	0.000236	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	2.06e-05	0.000235	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.06e-05	0.000235	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	2.05e-05	0.000233	CbGpPWpGaD
Imatinib—CA9—Metabolism—ALB—focal segmental glomerulosclerosis	2.05e-05	0.000233	CbGpPWpGaD
Imatinib—SLC22A1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.04e-05	0.000232	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TGFB1—focal segmental glomerulosclerosis	2.02e-05	0.00023	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.01e-05	0.000229	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.99e-05	0.000226	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.96e-05	0.000223	CbGpPWpGaD
Imatinib—LCK—Disease—LPL—focal segmental glomerulosclerosis	1.94e-05	0.000221	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.94e-05	0.000221	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.93e-05	0.00022	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	1.93e-05	0.00022	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	1.9e-05	0.000217	CbGpPWpGaD
Imatinib—ALB—Hemostasis—FN1—focal segmental glomerulosclerosis	1.9e-05	0.000216	CbGpPWpGaD
Imatinib—PDGFRB—Disease—NOS2—focal segmental glomerulosclerosis	1.89e-05	0.000215	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.88e-05	0.000214	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.88e-05	0.000214	CbGpPWpGaD
Imatinib—ALB—Hemostasis—NOS2—focal segmental glomerulosclerosis	1.87e-05	0.000213	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.87e-05	0.000213	CbGpPWpGaD
Imatinib—KIT—Disease—SERPINE1—focal segmental glomerulosclerosis	1.87e-05	0.000213	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—LIPC—focal segmental glomerulosclerosis	1.85e-05	0.000211	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.81e-05	0.000206	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.79e-05	0.000204	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.78e-05	0.000203	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.78e-05	0.000203	CbGpPWpGaD
Imatinib—PDGFRA—Disease—SERPINE1—focal segmental glomerulosclerosis	1.77e-05	0.000201	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.75e-05	0.000199	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.7e-05	0.000194	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.69e-05	0.000193	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.68e-05	0.000191	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.67e-05	0.00019	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.65e-05	0.000188	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CTGF—focal segmental glomerulosclerosis	1.63e-05	0.000185	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.61e-05	0.000183	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.6e-05	0.000183	CbGpPWpGaD
Imatinib—ALB—Metabolism—LIPC—focal segmental glomerulosclerosis	1.59e-05	0.000181	CbGpPWpGaD
Imatinib—PDGFRB—Disease—SERPINE1—focal segmental glomerulosclerosis	1.59e-05	0.000181	CbGpPWpGaD
Imatinib—ALB—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	1.58e-05	0.00018	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—LPL—focal segmental glomerulosclerosis	1.58e-05	0.000179	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.57e-05	0.000179	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—LPL—focal segmental glomerulosclerosis	1.56e-05	0.000178	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—LPL—focal segmental glomerulosclerosis	1.56e-05	0.000178	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.53e-05	0.000174	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.53e-05	0.000174	CbGpPWpGaD
Imatinib—LCK—Disease—NOS2—focal segmental glomerulosclerosis	1.52e-05	0.000173	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—LPL—focal segmental glomerulosclerosis	1.51e-05	0.000172	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.5e-05	0.000171	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.49e-05	0.000169	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—LPL—focal segmental glomerulosclerosis	1.45e-05	0.000166	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.45e-05	0.000165	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—LIPC—focal segmental glomerulosclerosis	1.43e-05	0.000163	CbGpPWpGaD
Imatinib—ALB—Metabolism—CTGF—focal segmental glomerulosclerosis	1.4e-05	0.00016	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.4e-05	0.00016	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	1.4e-05	0.000159	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.37e-05	0.000156	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.36e-05	0.000155	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AGT—focal segmental glomerulosclerosis	1.35e-05	0.000154	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.34e-05	0.000153	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AGT—focal segmental glomerulosclerosis	1.34e-05	0.000152	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AGT—focal segmental glomerulosclerosis	1.33e-05	0.000152	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—LIPC—focal segmental glomerulosclerosis	1.32e-05	0.00015	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.31e-05	0.000149	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.31e-05	0.000149	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—LIPC—focal segmental glomerulosclerosis	1.3e-05	0.000149	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AGT—focal segmental glomerulosclerosis	1.29e-05	0.000147	CbGpPWpGaD
Imatinib—ALB—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.29e-05	0.000147	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.29e-05	0.000147	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.29e-05	0.000147	CbGpPWpGaD
Imatinib—LCK—Disease—SERPINE1—focal segmental glomerulosclerosis	1.28e-05	0.000145	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CTGF—focal segmental glomerulosclerosis	1.26e-05	0.000143	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AGT—focal segmental glomerulosclerosis	1.24e-05	0.000142	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.24e-05	0.000141	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	1.23e-05	0.00014	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.19e-05	0.000136	CbGpPWpGaD
Imatinib—KIT—Disease—TGFB1—focal segmental glomerulosclerosis	1.18e-05	0.000134	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.17e-05	0.000134	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.16e-05	0.000133	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.16e-05	0.000132	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CTGF—focal segmental glomerulosclerosis	1.16e-05	0.000132	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CTGF—focal segmental glomerulosclerosis	1.15e-05	0.000131	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.13e-05	0.000129	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—LPL—focal segmental glomerulosclerosis	1.13e-05	0.000129	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.13e-05	0.000128	CbGpPWpGaD
Imatinib—PDGFRA—Disease—TGFB1—focal segmental glomerulosclerosis	1.12e-05	0.000127	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.11e-05	0.000127	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	1.11e-05	0.000127	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.07e-05	0.000122	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.07e-05	0.000122	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.06e-05	0.00012	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—ALB—focal segmental glomerulosclerosis	1.03e-05	0.000118	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—ALB—focal segmental glomerulosclerosis	1.02e-05	0.000117	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—ALB—focal segmental glomerulosclerosis	1.02e-05	0.000117	CbGpPWpGaD
Imatinib—PDGFRB—Disease—TGFB1—focal segmental glomerulosclerosis	1e-05	0.000114	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1e-05	0.000114	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1e-05	0.000114	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TGFB1—focal segmental glomerulosclerosis	9.95e-06	0.000113	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—ALB—focal segmental glomerulosclerosis	9.94e-06	0.000113	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	9.81e-06	0.000112	CbGpPWpGaD
Imatinib—ALB—Metabolism—LPL—focal segmental glomerulosclerosis	9.72e-06	0.000111	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AGT—focal segmental glomerulosclerosis	9.65e-06	0.00011	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—ALB—focal segmental glomerulosclerosis	9.54e-06	0.000109	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	9.47e-06	0.000108	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	9.04e-06	0.000103	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	8.94e-06	0.000102	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—LPL—focal segmental glomerulosclerosis	8.73e-06	9.94e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	8.6e-06	9.8e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	8.54e-06	9.72e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	8.52e-06	9.7e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—AGT—focal segmental glomerulosclerosis	8.32e-06	9.47e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	8.25e-06	9.4e-05	CbGpPWpGaD
Imatinib—LCK—Disease—TGFB1—focal segmental glomerulosclerosis	8.06e-06	9.18e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—LPL—focal segmental glomerulosclerosis	8.03e-06	9.14e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—LPL—focal segmental glomerulosclerosis	7.96e-06	9.06e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	7.81e-06	8.9e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	7.57e-06	8.62e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AGT—focal segmental glomerulosclerosis	7.46e-06	8.5e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ALB—focal segmental glomerulosclerosis	7.41e-06	8.44e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	7.29e-06	8.3e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	7.04e-06	8.01e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	6.97e-06	7.95e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AGT—focal segmental glomerulosclerosis	6.87e-06	7.82e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	6.85e-06	7.8e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AGT—focal segmental glomerulosclerosis	6.81e-06	7.75e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—LPL—focal segmental glomerulosclerosis	6.8e-06	7.75e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AGT—focal segmental glomerulosclerosis	5.82e-06	6.63e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ALB—focal segmental glomerulosclerosis	5.73e-06	6.53e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	5.65e-06	6.43e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	5.59e-06	6.37e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ALB—focal segmental glomerulosclerosis	5.27e-06	6e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	5.25e-06	5.98e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ALB—focal segmental glomerulosclerosis	5.22e-06	5.95e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	4.49e-06	5.11e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ALB—focal segmental glomerulosclerosis	4.46e-06	5.08e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	3.44e-06	3.92e-05	CbGpPWpGaD
